Home » Stocks » Allakos

Allakos Inc. (ALLK)

Stock Price: $68.71 USD -0.16 (-0.23%)
Updated Jul 9, 2020 12:16 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 3.35B
Revenue (ttm) n/a
Net Income (ttm) -93.24M
Shares Out 48.77M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $68.71
Previous Close $68.86
Change ($) -0.16
Change (%) -0.23%
Day's Open 69.05
Day's Range 67.60 - 70.97
Day's Volume 44,367
52-Week Range 30.32 - 139.99

More Stats

Market Cap 3.35B
Enterprise Value 2.87B
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 48.77M
Float 24.59M
EPS (basic) -1.99
EPS (diluted) -2.00
FCF / Share -1.42
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.00M
Short Ratio 24.53
Short % of Float 38.47%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.82
Revenue n/a
Operating Income -100.36M
Net Income -93.24M
Free Cash Flow -69.04M
Net Cash 479.81M
Net Cash / Share 9.84
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -18.32%
ROE -28.87%
ROIC -34.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 2

Analyst Consensus: Overweight

Price Target

(31.24% upside)
Current: 68.71
Target: 90.17
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-91.42-45.72-22.25-17.06
Net Income-85.37-43.54-23.55-17.10
Shares Outstanding45.1919.831.621.31
Earnings Per Share-1.89-2.20-14.54-13.03
Operating Cash Flow-63.01-38.45-22.57-17.58
Capital Expenditures-0.77-6.95-0.26-0.23
Free Cash Flow-63.78-45.40-22.83-17.81
Cash & Equivalents49617985.2113.42
Total Debt---4.99
Net Cash / Debt49617985.218.43
Book Value496184-58.77-36.44
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Allakos Inc.
Country United States
Employees 96
CEO Robert Alexander

Stock Information

Ticker Symbol ALLK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALLK
IPO Date July 19, 2018


Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.